primary%20biliary%20cholangitis
PRIMARY BILIARY CHOLANGITIS

Primary biliary cholangitis (formerly primary biliary cirrhosis) is a chronic, progressive, autoimmune, cholestatic liver disease more common in middle-aged women. It is characterized by destruction of small to medium bile ducts leading to cholestasis and frequently, end-stage liver disease.
Diagnostic features are chronic biochemical cholestasis, presence of antimitochondrial antibodies and the characteristic liver biopsy findings.


 

Pharmacotherapy

  • All PBC patients with abnormal liver biochemistry are possible candidates for specific therapy  
  • Treatment goals are to prevent end-stage liver disease and to manage PBC-associated symptoms affecting patient’s quality of life 

Ursodeoxycholic Acid (UDCA)

  • Patients with abnormal liver biochemistry (regardless of histologic stage) and confirmed PBC should be given UDCA
  • Chief medication used to deter disease progression
  • Action: Increases the rate of transport of intracellular bile acids across the liver cell and into the canaliculus, thus reducing hydrophobic bile acid levels inside hepatic cells
    • May have anti-inflammatory, choleretic, cytoprotective and immunomodulatory effects
  • Results in significant improvement in biochemical markers of cholestasis (ALP, GGT, bilirubin, AST, ALT); decreased serum LDL cholesterol; decreased AMA titers
  • UDCA therapy results in a significant increase in survival after up to 4 years of treatment, thus delaying the need for liver transplantation
    • The biggest benefit is seen in those with the most severe disease
  • UDCA also protects PBC patients from developing hepatoma
  • UDCA use may have little effect on symptoms
    • The drug may delay development of portal hypertension
    • Treatment reduces the rate of development of esophageal varices, but does not reduce the rate of bleeding from these varices
    • There has been no evidence that UDCA decreases fatigue or pruritus, or that it has any benefit on osteoporosis or autoimmune features associated with PBC
  • Patient compliance may be better when a single daily dose is used, compared to divided doses
    • Single daily dose is just as effective as divided doses
  • Assess biochemical response after 1 year of UDCA therapy 

Obeticholic Acid (OCA)

  • May be used as monotherapy in patients intolerant to UDCA or in combination with UDCA in patients with inadequate response to a year of UDCA therapy 
  • Action: Modulates the synthesis, absorption, transport, secretion and metabolism of bile acids resulting to a choleretic effect 
  • Liver chemistries and inflammatory markers improved with therapy 
  • Most common adverse effect is pruritus 
  • Use is not recommended in decompensated PBC

Other Agents

  • Fibrates may be considered as an off-label therapy in patients with inadequate response to UDCA therapy but not in those with decompensated liver disease
  • Immunosuppressive drugs have been studied for PBC because of the autoimmune nature of the disease
    • Immunosuppressive therapy, in addition to UDCA, may benefit PBC patients with AIH   
    • Corticosteroids combined with UDCA had shown improvement of liver function serum parameters and histologic grades in controlled trials
      • Budesonide in combination with UDCA had been shown in clinical trials to improve liver function serum parameters as well as liver histology in patients with grade I-III fibrosis
    • A few studies have shown some benefits from treatment with Azathioprine and Ciclosporin but adverse effects may limit usefulness
    • Studies have found insufficient evidence regarding the benefit of additional treatment with Colchicine, Methotrexate, or Silymarin
  • Mycophenolate mofetil, Chlorambucil, Penicillamine, Thalidomide, Seladelpar, leukotriene antagonists, antiretrovirals, molecular therapies, and monoclonal antibodies are promising therapies that are currently being studied
Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Gastroenterology - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
15 Jul 2019
Fluticasone, swallowed from a multidose inhaler, and oral viscous budesonide slurry have comparable efficacies as initial treatment for eosinophilic oesophagitis, a recent study has found.
31 May 2019
Co-therapy with proton pump inhibitors (PPIs) in patients receiving low-dose anticoagulation and/or aspirin for stable cardiovascular disease confers no benefit for upper gastrointestinal events but may reduce bleeding due to gastroduodenal lesions, a study has shown.
29 Jun 2019
Monotherapy with a proton pump inhibitor appears to be effective in the treatment of functional dyspepsia symptoms associated with gastro-oesophageal reflux disease, according to a study.
07 Aug 2019
The combination of metformin, nystatin, linagliptin, rivaroxaban and a high-protein diet is the main cause of nasoenteral tube obstruction, with corresponding odds ratios of 2.0, 3.1, 4.3, 2.4 and 1.9, according to a recent study.